On October 22, 2024, RedHill Biopharma announced a collaboration with Duke University to develop Opaganib as a treatment for phosgene inhalation injuries, which can cause severe respiratory issues. This collaboration supports multiple studies to assess its effectiveness as a potential medical countermeasure against toxic exposure.